Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
Related Questions
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESKD and DM2?
Does your decision to start or continue Ozempic therapy in patients with diabetic retinopathy depend on the severity of the retinopathy?
Would you consider GLP1 R agonist therapy in a patient with a history of severe gallstone pancreatitis that is now post cholecystectomy?
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
Are recurrent UTIs a contraindication to SGLT2i use?
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
How do you counsel patients on the use of compounded weight loss medications?
Will Omnipod 5 work well in patients receiving bursts of corticosteroids or in those on hemodialysis?
